55
views
0
recommends
+1 Recommend
0 collections
    4
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rational design of multi-targeted drug combinations is a promising strategy to tackle the drug resistance problem for many complex disorders. A drug combination is usually classified as synergistic or antagonistic, depending on the deviation of the observed combination response from the expected effect calculated based on a reference model of non-interaction. The existing reference models were proposed originally for low-throughput drug combination experiments, which make the model assumptions often incompatible with the complex drug interaction patterns across various dose pairs that are typically observed in large-scale dose–response matrix experiments. To address these limitations, we proposed a novel reference model, named zero interaction potency (ZIP), which captures the drug interaction relationships by comparing the change in the potency of the dose–response curves between individual drugs and their combinations. We utilized a delta score to quantify the deviation from the expectation of zero interaction, and proved that a delta score value of zero implies both probabilistic independence and dose additivity. Using data from a large-scale anticancer drug combination experiment, we demonstrated empirically how the ZIP scoring approach captures the experimentally confirmed drug synergy while keeping the false positive rate at a low level. Further, rather than relying on a single parameter to assess drug interaction, we proposed the use of an interaction landscape over the full dose–response matrix to identify and quantify synergistic and antagonistic dose regions. The interaction landscape offers an increased power to differentiate between various classes of drug combinations, and may therefore provide an improved means for understanding their mechanisms of action toward clinical translation.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: not found
          • Article: not found

          The problem of synergism and antagonism of combined drugs.

          S. Loewe (1953)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            What is synergy?

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Kinesins and cancer.

              Kinesins are a family of molecular motors that travel unidirectionally along microtubule tracks to fulfil their many roles in intracellular transport or cell division. Over the past few years kinesins that are involved in mitosis have emerged as potential targets for cancer drug development. Several compounds that inhibit two mitotic kinesins (EG5 (also known as KIF11) and centromere-associated protein E (CENPE)) have entered Phase I and II clinical trials either as monotherapies or in combination with other drugs. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the range of kinesin-based drug targets may expand in the future.
                Bookmark

                Author and article information

                Contributors
                Journal
                Comput Struct Biotechnol J
                Comput Struct Biotechnol J
                Computational and Structural Biotechnology Journal
                Research Network of Computational and Structural Biotechnology
                2001-0370
                25 September 2015
                2015
                25 September 2015
                : 13
                : 504-513
                Affiliations
                Institute for Molecular Medicine Finland (FIMM), FI-00014, University of Helsinki, Finland
                Article
                S2001-0370(15)00042-2
                10.1016/j.csbj.2015.09.001
                4759128
                26949479
                2535572b-3b4a-41a0-978b-4cb51dc1cd77
                © 2015 Yadav et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology.

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 15 June 2015
                : 11 September 2015
                : 14 September 2015
                Categories
                Research Article

                drug combination scoring,interaction landscape,dose–response matrix,high-throughput screening

                Comments

                Comment on this article